Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$158.56 USD
-2.08 (-1.29%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $158.55 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JNJ 158.56 -2.08(-1.29%)
Will JNJ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Time for Healthcare ETFs?
Other News for JNJ
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
IN BRIEF: J&J subsidiary's Rybrevant recommended for further approval
AbbVie: Growth Is Still A Better Choice
Video: Dow Movers: JNJ, MCD
Stocks Going Ex Dividend In August 2024